Moxifloxacin Krka (Moxifloxacin)

Moxifloxacin is a fluoroquinolone antibiotic used to treat bacterial infections in several organ systems.

• Community‑acquired bacterial pneumonia: rapid bacterial eradication leading to clinical improvement and reduced mortality.
• Acute bacterial sinusitis: eradicates causative pathogens, relieving sinus inflammation and symptoms.
• Skin and soft tissue infections: eliminates susceptible organisms, promoting wound healing and infection control.
• Intra‑abdominal infections: provides broad‑spectrum coverage of Gram‑negative and anaerobic bacteria, aiding recovery.
• Complicated urinary tract infections: clears resistant uropathogens, improving urinary symptoms and preventing complications.

• Moxifloxacin exerts its antibacterial activity by binding to the bacterial enzymes DNA gyrase (topoisomerase II) and topoisomerase IV. Inhibition of these enzymes interferes with DNA supercoiling and replication, preventing bacterial chromosome segregation and transcription. The resulting DNA damage leads to rapid bacterial cell death, providing a bactericidal effect against a wide range of Gram‑positive, Gram‑negative and atypical pathogens. It is active against common respiratory pathogens such as Streptococcus pneumoniae and Haemophilus influenzae.

Moxifloxacin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea
• Diarrhea
• Headache
• Injection site pain

Serious or Rare Side Effects

• Tendon rupture or tendinitis
• QT interval prolongation
• Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome)
• Clostridioides difficile‑associated colitis

When using Moxifloxacin, clinicians should observe several precautionary measures to minimize risk.

• Assess renal and hepatic function: adjust therapy in patients with impairment.
• Monitor cardiac status: avoid in patients with known QT prolongation or electrolyte disturbances.
• Avoid use in patients with a history of tendon disorders: risk of tendon rupture.
• Use cautiously in the elderly and in those receiving concomitant nephrotoxic or ototoxic drugs.
• Review concomitant medications that may prolong QT interval: consider alternative agents.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Moxifloxacin can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Antacids or supplements containing aluminum, magnesium, calcium, or iron: reduce moxifloxacin absorption.
• Warfarin: potentiates anticoagulant effect, increasing bleeding risk.
• Cyclosporine: raises moxifloxacin plasma levels, heightening toxicity.

Moderate Interactions (Monitor Closely)

• NSAIDs: may increase risk of central nervous system stimulation.
• Diuretics causing hypokalemia: can exacerbate QT interval prolongation.
• Oral contraceptives: possible reduction in contraceptive effectiveness.